IDX 184 (Idenix)trial for Hepatitis C halted by FDA for suspected cardiotoxicity

IDX 184 is a drug from Idenix Pharmaceuticals for treatment of Hepatitis C. The development of the drug has been placed on partial hold by the FDA as the drug may be linked to serious cardiac related adverse events. Idenix maintains that no evidence of cardiotoxicity has been found in its trials but will perform cardiac tests on its 67 patients that have been treated with the drug.A competitor drug in the same class, nucleotide polymerase inhibitors has had its trial halted for the same reason.